vs
Side-by-side financial comparison of Axil Brands, Inc. (AXIL) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $8.1M, roughly 1.1× Axil Brands, Inc.). Axil Brands, Inc. runs the higher net margin — 8.7% vs -60.3%, a 69.0% gap on every dollar of revenue. On growth, Axil Brands, Inc. posted the faster year-over-year revenue change (5.2% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $906.4K). Over the past eight quarters, Axil Brands, Inc.'s revenue compounded faster (12.1% CAGR vs -6.7%).
Axil Brands, Inc. is a U.S.-headquartered company that designs, manufactures and markets premium hearing protection products, audio enhancement devices and personal audio accessories. Its offerings include custom-fit earplugs, Bluetooth-enabled hearing buds for work, sports and leisure use, serving both consumer and professional segments across global markets.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
AXIL vs PLX — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $9.1M |
| Net Profit | $704.9K | $-5.5M |
| Gross Margin | 68.1% | 49.4% |
| Operating Margin | 11.1% | -51.1% |
| Net Margin | 8.7% | -60.3% |
| Revenue YoY | 5.2% | -49.9% |
| Net Profit YoY | 11.2% | -184.8% |
| EPS (diluted) | $0.09 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.1M | $9.1M | ||
| Q3 25 | $6.9M | $17.9M | ||
| Q2 25 | $5.8M | $15.7M | ||
| Q1 25 | $6.9M | $10.1M | ||
| Q4 24 | $7.7M | $18.2M | ||
| Q3 24 | $5.9M | $18.0M | ||
| Q2 24 | $6.5M | $13.5M | ||
| Q1 24 | $6.5M | — |
| Q4 25 | $704.9K | $-5.5M | ||
| Q3 25 | $334.3K | $2.4M | ||
| Q2 25 | $-245.6K | $164.0K | ||
| Q1 25 | $576.7K | $-3.6M | ||
| Q4 24 | $633.7K | $6.5M | ||
| Q3 24 | $-109.8K | $3.2M | ||
| Q2 24 | $49.5K | $-2.2M | ||
| Q1 24 | $781.1K | — |
| Q4 25 | 68.1% | 49.4% | ||
| Q3 25 | 67.6% | 53.4% | ||
| Q2 25 | 70.0% | 62.5% | ||
| Q1 25 | 71.7% | 19.1% | ||
| Q4 24 | 71.1% | 78.7% | ||
| Q3 24 | 71.0% | 53.4% | ||
| Q2 24 | 71.5% | 29.8% | ||
| Q1 24 | 71.5% | — |
| Q4 25 | 11.1% | -51.1% | ||
| Q3 25 | 6.0% | 11.9% | ||
| Q2 25 | 0.8% | 7.5% | ||
| Q1 25 | 8.4% | -41.0% | ||
| Q4 24 | 8.7% | 39.6% | ||
| Q3 24 | -2.4% | 22.2% | ||
| Q2 24 | 2.6% | -18.0% | ||
| Q1 24 | -1.6% | — |
| Q4 25 | 8.7% | -60.3% | ||
| Q3 25 | 4.9% | 13.2% | ||
| Q2 25 | -4.3% | 1.0% | ||
| Q1 25 | 8.3% | -35.8% | ||
| Q4 24 | 8.2% | 35.6% | ||
| Q3 24 | -1.9% | 18.0% | ||
| Q2 24 | 0.8% | -16.4% | ||
| Q1 24 | 12.1% | — |
| Q4 25 | $0.09 | $-0.06 | ||
| Q3 25 | $0.04 | $0.03 | ||
| Q2 25 | $-0.03 | $0.00 | ||
| Q1 25 | $0.07 | $-0.05 | ||
| Q4 24 | $0.08 | $0.10 | ||
| Q3 24 | $-0.02 | $0.03 | ||
| Q2 24 | $0.11 | $-0.03 | ||
| Q1 24 | $0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $14.7M |
| Total DebtLower is stronger | $138.3K | — |
| Stockholders' EquityBook value | $11.1M | $48.2M |
| Total Assets | $16.2M | $82.3M |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.0M | $14.7M | ||
| Q3 25 | $4.1M | $13.6M | ||
| Q2 25 | $4.8M | $17.9M | ||
| Q1 25 | $4.7M | $19.5M | ||
| Q4 24 | $5.2M | $19.8M | ||
| Q3 24 | $4.1M | $27.4M | ||
| Q2 24 | $3.3M | $23.4M | ||
| Q1 24 | $4.9M | — |
| Q4 25 | $138.3K | — | ||
| Q3 25 | $139.2K | — | ||
| Q2 25 | $140.2K | — | ||
| Q1 25 | $141.0K | — | ||
| Q4 24 | $143.3K | — | ||
| Q3 24 | $144.3K | — | ||
| Q2 24 | $146.6K | — | ||
| Q1 24 | — | — |
| Q4 25 | $11.1M | $48.2M | ||
| Q3 25 | $10.2M | $52.9M | ||
| Q2 25 | $9.7M | $49.9M | ||
| Q1 25 | $9.7M | $45.2M | ||
| Q4 24 | $8.8M | $43.2M | ||
| Q3 24 | $7.9M | $32.4M | ||
| Q2 24 | $7.7M | $28.6M | ||
| Q1 24 | $8.8M | — |
| Q4 25 | $16.2M | $82.3M | ||
| Q3 25 | $15.4M | $82.3M | ||
| Q2 25 | $12.9M | $78.5M | ||
| Q1 25 | $13.0M | $73.9M | ||
| Q4 24 | $13.7M | $73.4M | ||
| Q3 24 | $11.4M | $61.6M | ||
| Q2 24 | $11.0M | $91.5M | ||
| Q1 24 | $12.7M | — |
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $934.8K | $2.0M |
| Free Cash FlowOCF − Capex | $906.4K | $1.6M |
| FCF MarginFCF / Revenue | 11.1% | 17.8% |
| Capex IntensityCapex / Revenue | 0.3% | 4.4% |
| Cash ConversionOCF / Net Profit | 1.33× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $934.8K | $2.0M | ||
| Q3 25 | $-739.2K | $-3.7M | ||
| Q2 25 | $194.4K | $-5.2M | ||
| Q1 25 | $-169.9K | $-5.1M | ||
| Q4 24 | $1.0M | $4.0M | ||
| Q3 24 | $897.3K | $4.1M | ||
| Q2 24 | $-336.6K | $-3.6M | ||
| Q1 24 | $-912.8K | — |
| Q4 25 | $906.4K | $1.6M | ||
| Q3 25 | $-747.6K | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | $-258.2K | $-5.4M | ||
| Q4 24 | $941.1K | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | $-394.9K | $-3.8M | ||
| Q1 24 | $-922.1K | — |
| Q4 25 | 11.1% | 17.8% | ||
| Q3 25 | -10.9% | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | -3.7% | -53.0% | ||
| Q4 24 | 12.2% | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | -6.1% | -28.1% | ||
| Q1 24 | -14.3% | — |
| Q4 25 | 0.3% | 4.4% | ||
| Q3 25 | 0.1% | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | 1.3% | 3.0% | ||
| Q4 24 | 0.9% | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | 0.9% | 1.3% | ||
| Q1 24 | 0.1% | — |
| Q4 25 | 1.33× | — | ||
| Q3 25 | -2.21× | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | -0.29× | — | ||
| Q4 24 | 1.59× | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | -6.80× | — | ||
| Q1 24 | -1.17× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXIL
| Hearing Enhancement And Protection | $7.8M | 95% |
| Other | $378.9K | 5% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
